Sinusitis Treatment Market (Treatment: Analgesics, Antihistamines, Corticosteroids, Antibiotics, Sulphonamides, Quinolones, and Surgery; Disease Type: Acute Sinusitis, Sub-acute Sinusitis, and Chronic Sinusitis; Route of Administration: Topical, Nasal, Oral, and Injectable; and Distribution Channel: Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2030

Description

Distinguishing Symptoms of COVID-19, Sinus Gain Importance with Telemedicine

Since sinus infection and COVID-19 have similar symptoms, there is a need to differentiate between the two. Stakeholders in the sinusitis treatment market are increasing awareness that coronavirus is associated with some of the striking symptoms such as dry cough, whereas sinus is linked with cough involving mucus. Other striking symptoms such as chills & aches and loss of smell or taste are helping people to distinguish between the two. As such, there is a lack of evidence whether COVID-19 causes sinusitis.

Due to the symptoms of sinus overlapping with that of COVID-19, stakeholders in the sinusitis treatment market are increasing awareness about telemedicine and e-health to reduce the load on healthcare professionals and minimize clinical visits. Digital consultations are growing rapidly among individuals living in urban cities. Stakeholders in the value chain are mapping future growth opportunities in telemedicine to increase its penetration in rural regions.

R&D in Antibiotics Resulting in Better Alternative Interventions

There is a growing need to re-think acute sinusitis treatment in adults. The current over-prescribing of antibiotics has led to an increase in drug-resistant pathogens, which has become an urgent public health threat in the U.S. This is leading to increased morbidity, mortality, and costs for patients & healthcare systems. Hence, companies in the sinusitis treatment market are increasing their R&D efforts to offer better alternative interventions to treat the symptoms of patients.

Antibiotics are predicted to dominate the second highest revenue among all treatment types in the market. However, current studies examining the efficacy of antibiotics for acute sinusitis have included generally healthy adults, and most have excluded patients with severe illnesses or co-existing conditions such as diabetes or pulmonary diseases. This has stressed on the importance of thorough research studies to improve clinical outcomes with the help of antibiotics in the sinusitis treatment market.

Improved Intra-nasal Drug Delivery Helps to Improve Patient Quality of Life

The high prevalence of chronic rhinosinusitis (CRS) in the U.S. is creating lucrative revenue opportunities for companies in the sinusitis treatment market. Nasus Medical - a startup born out of Stanford Biodesign and now a Fogarty Institute Company is tapping incremental opportunities in the CRS treatment by developing a solution for improved intra-nasal drug delivery. Competitor companies are taking cues from such innovations to develop advanced devices that allow patients to treat themselves at home to minimize symptoms of chronic sinusitis in its early stages.

Since nasal steroid sprays are largely ineffective, given that they only reach the front most portion of the nasal cavity, companies in the sinusitis treatment market are increasing their R&D activities to develop devices that push past the nasal inflammation. These devices help to access the optimal anatomic target to make sprays more effective.

New Nasal Sprays Deliver Drug in Hard-to-reach Cavities of Patients’ Sinuses

The unique nasal spray designs are a fast growing phenomenon in the global sinusitis treatment market. Innovators are gaining awareness that stakeholders need to go beyond drug innovations and focus more on ways to deliver it in hard to reach cavities of the patients’ sinuses. The Optinose XHANCE is gaining popularity for overcoming this challenge and developing a nasal spray that patients can use at the comfort of their home. Since the symptoms of acute sinusitis are fairly severe, and can be measured to the same magnitude of harm to a patient’s life as other chronic diseases, med-tech companies are innovating in new designs of nasal sprays.

Analysts’ Viewpoint

Healthcare professionals and institutes are increasing efforts to educate people about the differentiating symptoms of sinus and COVID-19. The sinusitis treatment market is expected to reach US$ 4.5 Bn by 2031 and expand at a modest CAGR of ~4% during the assessment period. However, high-dose antibiotics and steroid pills lead to significant side effects. Hence, companies should develop devices that improve intra-nasal drug delivery using innovative devices and minimize side effects of antibiotics. Med-tech companies in the sinusitis treatment market are boosting their R&D capacities to develop devices that deploy bi-directional exhalation to allow fluticasone to move around the obstructions in the nasal cavity.

Sinusitis Treatment Market: Overview

Sinuses are a connected system of air-filled cavities located in the skull. Sinusitis is an inflammation of the sinus lining caused by bacteria, virus, fungi, and microbes. Bacterial sinusitis is less common than viral sinusitis and requires antibiotics, while viral sinusitis is most common and does not require antibiotics.

Fungal sinusitis is also known as allergic fungal sinusitis and is caused by aspergillosis fungi. Possible symptoms of sinus infection are nasal obstruction, discolored nasal discharge, and facial pain that lasts for seven days or more. Facial pain is a common symptom in sinusitis. A patient could feel pain around the eye, forehead, nose, and root of teeth. There are three primary types of sinusitis: acute sinusitis, sub-acute sinusitis, and chronic sinusitis.

Acute rhinosinusitis is a general disease with global prevalence. The disease is a major burden on health services. Rhinosinusitis is a major health problem globally. It is an infection of the nasal passages and paranasal sinuses.

Primary care physicians usually tend to think of sinusitis as an acute bacterial infection. Hence, antibiotics are prescribed to 92% of patients in the U.K. and 85% to 98% of sinusitis patients in the U.S. In 2003, the number of medical prescriptions for acute bacterial sinusitis was around 7.6 million in Germany. In France, around 7% of all antibiotics are prescribed to treat suspected acute bacterial sinusitis.

The annual cost of treatment in the U.K. is GBP 10 Mn (EUR 14.7 Mn, US$ 20 Mn). In 1996, the total cost of prescription and non‐prescription medications used for the treatment of sinusitis in the U.S. was around US$ 3.39 Bn (EUR 2.5 Bn, GBP 1.7 Bn). Rhinosinusitis accounted for around 12 million to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the growth of the global sinusitis treatment market.

Market Segmentation: Sinusitis Treatment Market

In terms of treatment, the global sinusitis treatment market has been classified into analgesics, antihistamines, corticosteroids, antibiotics, sulphonamides, quinolones, and surgery. Antibiotics have been split into cephalosporin, penicillin, and macrolide. The surgery segment has been bifurcated into endoscopy and balloon sinusplasty. Antihistamines are beneficial for reducing ostiomeatal obstruction in patients with allergies and acute sinusitis.

Based on disease type, the global sinusitis treatment market has been categorized into acute sinusitis, sub-acute sinusitis, and chronic sinusitis. Acute sinusitis is generally caused by common cold. Signs and symptoms could include nasal obstruction and congestion, which may block a patient's sinuses and prevent drainage of mucus. Hence, rise in cases of common cold & flu lead to increase in cases of acute sinusitis, which, in turn, propels the global market.

In terms of route of administration, the global sinusitis treatment market has been divided into topical, nasal, oral, and injectable. Oral administration of medication is a cost-effective, convenient, and most commonly used route of administration. The primary site of drug absorption is usually the small intestine, and the bioavailability of the medication is impacted by the amount of drug absorbed across the intestinal epithelium.

Based on distribution channel, the global sinusitis treatment market has been classified into online pharmacies, retail pharmacies, and hospital pharmacies. Retail pharmacies are preferred due to faster services and brand availability.

Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The sinusitis treatment market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Sinusitis Treatment Market

In terms of region, the global sinusitis treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2021 to 2031, with their CAGRs from 2021 to 2031

The study also offers a list of recommendations, highlights, and useful insights of the global sinusitis treatment market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process

Sinusitis Treatment Market: Major Players

The sinusitis treatment market report concludes with the company profiles section, which includes key information about major players in the global sinusitis treatment market

Leading players analyzed in the report include

  • Sun Pharmaceutical Industries, Inc.
  • Pfizer, Inc.
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • Fresenius Kabi USA, LLC
  • Dr. Reddy's Laboratories, Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Abbott Laboratories
  • Bayer AG
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • Merck & Co, Inc.
  • AstraZeneca plc
  • Amneal Pharmaceuticals LLC
  • GlaxoSmithKline plc.
  • Aurobindo Pharma
  • Hikma Pharmaceuticals plc
  • Wockhardt
  • Mylan N.V.

Each of these players has been profiled in the sinusitis treatment market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Key Questions Answered in Sinusitis Treatment Market Report

  • What is the sales/revenue generated by sinusitis treatment across all regions during the forecast period?
  • What are the opportunities in the global sinusitis treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which treatment segment is expected to generate the highest revenue globally in 2030?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Sinusitis Treatment Market – Segmentation

Disease Type

  • Acute Sinusitis
  • Sub-acute Sinusitis
  • Chronic Sinusitis

Treatment

  • Analgesics
  • Antibiotics
  • Cephalosporin
  • Macrolide
  • Penicillin
  • Antihistamines
  • Surgery
  • Endoscopy
  • Balloon Sinusplasty
  • Corticosteroids
  • Sulphonamides
  • Quinolones

Route of Administration

  • Topical
  • Nasal
  • Oral
  • Injectable

Distribution Channel

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sinusitis Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Sinusitis Treatment Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Clinical Trials & Regulatory Approvals Analysis

    5.2. List of Brand / Product Approved

    5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    5.4. Technological Advancements

    5.5. Disease Prevalence & Incidence

6. Global Sinusitis Treatment Market Analysis and Forecast, by Treatment

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment, 2017–2031

        6.3.1. Antibiotics

            6.3.1.1. Cephalosporin

            6.3.1.2. Penicillin

            6.3.1.3. Macrolide

        6.3.2. Surgery

            6.3.2.1. Endoscopy

            6.3.2.2. Balloon Sinusplasty

        6.3.3. Analgesics

        6.3.4. Antihistamines

        6.3.5. Corticosteroids

        6.3.6. Sulphonamides

        6.3.7. Quinolones

    6.4. Market Attractiveness Analysis, by Treatment 

7. Global Sinusitis Treatment Market Analysis and Forecast, by Disease

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Disease, 2017–2031

        7.3.1. Acute Sinusitis

        7.3.2. Sub-acute Sinusitis

        7.3.3. Chronic Sinusitis

    7.4. Market Attractiveness Analysis, by Disease

8. Global Sinusitis Treatment Market Analysis and Forecast, by Route of Administration 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast By Route of Administration, 2017–2031

        8.3.1. Topical

        8.3.2. Nasal 

        8.3.3. Oral

        8.3.4. Injectable

    8.4. Market Attractiveness Analysis, by Route of Administration 

9. Global Sinusitis Treatment Market Analysis and Forecast, by Distribution Channel

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Distribution Channel, 2017–2031

        9.3.1. Online Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Hospital Pharmacies

    9.4. Market Attractiveness Analysis, by Distribution Channel 

10. Global Sinusitis Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3. Market Attractiveness Analysis, by Country/Region

11. North America Sinusitis Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment, 2017–2031

        11.2.1. Antibiotics

            11.2.1.1. Cephalosporin

            11.2.1.2. Penicillin

            11.2.1.3. Macrolide

        11.2.2. Surgery

            11.2.2.1. Endoscopy

            11.2.2.2. Balloon Sinusplasty

        11.2.3. Analgesics

        11.2.4. Antihistamines

        11.2.5. Corticosteroids

        11.2.6. Sulphonamides

        11.2.7. Quinolones

    11.3. Market Value Forecast, by Disease, 2017–2031

        11.3.1. Acute Sinusitis

        11.3.2. Sub-acute Sinusitis

        11.3.3. Chronic Sinusitis

    11.4. Market Value Forecast, by Route of Administration, 2017–2031

        11.4.1. Topical

        11.4.2. Nasal 

        11.4.3. Oral

        11.4.4. Injectable

    11.5. Market Value Forecast, by Distribution Channel, 2017–2031

        11.5.1. Online Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Hospital Pharmacies

    11.6. Market Value Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis 

        11.7.1. By Treatment 

        11.7.2. By Disease

        11.7.3. By Route of Administration 

        11.7.4. By Distribution Channel 

        11.7.5. By Country

12. Europe Sinusitis Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment, 2017–2031

        12.2.1. Antibiotics

            12.2.1.1. Cephalosporin

            12.2.1.2. Penicillin

            12.2.1.3. Macrolide

        12.2.2. Surgery

            12.2.2.1. Endoscopy

            12.2.2.2. Balloon Sinusplasty

        12.2.3. Analgesics

        12.2.4. Antihistamines

        12.2.5. Corticosteroids

        12.2.6. Sulphonamides

        12.2.7. Quinolones

    12.3. Market Value Forecast, by Disease, 2017–2031

        12.3.1. Acute Sinusitis

        12.3.2. Sub-acute Sinusitis

        12.3.3. Chronic Sinusitis

    12.4. Market Value Forecast, by Route of Administration, 2017–2031

        12.4.1. Topical

        12.4.2. Nasal 

        12.4.3. Oral

        12.4.4. Injectable

    12.5. Market Value Forecast, by Distribution Channel, 2017–2031

        12.5.1. Online Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Hospital Pharmacies

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis 

        12.7.1. By Treatment 

        12.7.2. By Disease

        12.7.3. By Route of Administration 

        12.7.4. By Distribution Channel 

        12.7.5. By Country/Sub-region

13. Asia Pacific Sinusitis Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment, 2017–2031

        13.2.1. Antibiotics

            13.2.1.1. Cephalosporin

            13.2.1.2. Penicillin

            13.2.1.3. Macrolide

        13.2.2. Surgery

            13.2.2.1. Endoscopy

            13.2.2.2. Balloon Sinusplasty

        13.2.3. Analgesics

        13.2.4. Antihistamines

        13.2.5. Corticosteroids

        13.2.6. Sulphonamides

        13.2.7. Quinolones

    13.3. Market Value Forecast, by Disease, 2017–2031

        13.3.1. Acute Sinusitis

        13.3.2. Sub-acute Sinusitis

        13.3.3. Chronic Sinusitis

    13.4. Market Value Forecast, by Route of Administration, 2017–2031

        13.4.1. Topical

        13.4.2. Nasal 

        13.4.3. Oral

        13.4.4. Injectable

    13.5. Market Value Forecast, by Distribution Channel, 2017–2031

        13.5.1. Online Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Hospital Pharmacies

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Market Attractiveness Analysis 

        13.7.1. By Treatment 

        13.7.2. By Disease

        13.7.3. By Route of Administration 

        13.7.4. By Distribution Channel 

        13.7.5. By Country/Sub-region

14. Latin America Sinusitis Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Treatment, 2017–2031

        14.2.1. Antibiotics

            14.2.1.1. Cephalosporin

            14.2.1.2. Penicillin

            14.2.1.3. Macrolide

        14.2.2. Surgery

            14.2.2.1. Endoscopy

            14.2.2.2. Balloon Sinusplasty

        14.2.3. Analgesics

        14.2.4. Antihistamines

        14.2.5. Corticosteroids

        14.2.6. Sulphonamides

        14.2.7. Quinolones

    14.3. Market Value Forecast, by Disease, 2017–2031

        14.3.1. Acute Sinusitis

        14.3.2. Sub-acute Sinusitis

        14.3.3. Chronic Sinusitis

    14.4. Market Value Forecast, by Route of Administration, 2017–2031

        14.4.1. Topical

        14.4.2. Nasal 

        14.4.3. Oral

        14.4.4. Injectable

    14.5. Market Value Forecast, by Distribution Channel, 2017–2031

        14.5.1. Online Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Hospital Pharmacies

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis 

        14.7.1. By Treatment 

        14.7.2. By Disease

        14.7.3. By Route of Administration 

        14.7.4. By Distribution Channel 

        14.7.5. By Country/Sub-region

15. Middle East & Africa Sinusitis Treatment Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Treatment, 2017–2031

        15.2.1. Antibiotics

            15.2.1.1. Cephalosporin

            15.2.1.2. Penicillin

            15.2.1.3. Macrolide

        15.2.2. Surgery

            15.2.2.1. Endoscopy

            15.2.2.2. Balloon Sinusplasty

        15.2.3. Analgesics

        15.2.4. Antihistamines

        15.2.5. Corticosteroids

        15.2.6. Sulphonamides

        15.2.7. Quinolones

    15.3. Market Value Forecast, by Disease, 2017–2031

        15.3.1. Acute Sinusitis

        15.3.2. Sub-acute Sinusitis

        15.3.3. Chronic Sinusitis

    15.4. Market Value Forecast, by Route of Administration, 2017–2031

        15.4.1. Topical

        15.4.2. Nasal 

        15.4.3. Oral

        15.4.4. Injectable

    15.5. Market Value Forecast, by Distribution Channel, 2017–2031

        15.5.1. Online Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Hospital Pharmacies

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis 

        15.7.1. By Treatment 

        15.7.2. By Disease

        15.7.3. By Route of Administration 

        15.7.4. By Distribution Channel 

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Share Analysis, by Company, 2020

    16.2. Company Profiles

        16.2.1. Sun Pharmaceutical Industries, Inc.

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Product Portfolio

            16.2.1.3. SWOT Analysis

            16.2.1.4. Strategic Overview

        16.2.2. Pfizer, Inc.

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Product Portfolio

            16.2.2.3. SWOT Analysis

            16.2.2.4. Strategic Overview

        16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Product Portfolio

            16.2.3.3. SWOT Analysis

            16.2.3.4. Strategic Overview

        16.2.4. Fresenius Kabi USA, LLC

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Product Portfolio

            16.2.4.3. SWOT Analysis

            16.2.4.4. Strategic Overview

        16.2.5. Dr. Reddy's Laboratories, Inc.

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Product Portfolio

            16.2.5.3. SWOT Analysis

            16.2.5.4. Strategic Overview

        16.2.6. Novartis AG

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Product Portfolio

            16.2.6.3. SWOT Analysis

            16.2.6.4. Strategic Overview

        16.2.7. Teva Pharmaceutical Industries Ltd.

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Product Portfolio

            16.2.7.3. SWOT Analysis

            16.2.7.4. Strategic Overview

        16.2.8. Sanofi

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Product Portfolio

            16.2.8.3. SWOT Analysis

            16.2.8.4. Strategic Overview

        16.2.9. Abbott Laboratories

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Product Portfolio

            16.2.9.3. SWOT Analysis

            16.2.9.4. Strategic Overview

        16.2.10. Bayer AG

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Product Portfolio

            16.2.10.3. SWOT Analysis

            16.2.10.4. Strategic Overview

        16.2.11. Eli Lilly And Company

            16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.11.2. Product Portfolio

            16.2.11.3. SWOT Analysis

            16.2.11.4. Strategic Overview

        16.2.12. Bristol-Myers Squibb

            16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.12.2. Product Portfolio

            16.2.12.3. SWOT Analysis

            16.2.12.4. Strategic Overview

        16.2.13. Merck & Co, Inc.

            16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.13.2. Product Portfolio

            16.2.13.3. SWOT Analysis

            16.2.13.4. Strategic Overview

        16.2.14. AstraZeneca plc

            16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.14.2. Product Portfolio

            16.2.14.3. SWOT Analysis

            16.2.14.4. Strategic Overview

        16.2.15. Amneal Pharmaceuticals LLC

            16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.15.2. Product Portfolio

            16.2.15.3. SWOT Analysis

            16.2.15.4. Strategic Overview

        16.2.16. GlaxoSmithKline plc

            16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.16.2. Product Portfolio

            16.2.16.3. SWOT Analysis

            16.2.16.4. Strategic Overview

        16.2.17. Apotex, Inc.

            16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.17.2. Product Portfolio

            16.2.17.3. SWOT Analysis

            16.2.17.4. Strategic Overview

        16.2.18. Hikma Pharmaceuticals plc

            16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.18.2. Product Portfolio

            16.2.18.3. SWOT Analysis

            16.2.18.4. Strategic Overview

        16.2.19. Wockhardt

            16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.19.2. Product Portfolio

            16.2.19.3. SWOT Analysis

            16.2.19.4. Strategic Overview

        16.2.20. Mylan N.V. 

            16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.20.2. Product Portfolio

            16.2.20.3. SWOT Analysis

            16.2.20.4. Strategic Overview

Choose License Type

Checkout Inquiry Sample